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Abstract
Background: Pre-exposure prophylaxis (PrEP) trials are evaluating regimens containing tenofovir-disoproxil fumarate (TDF)
for HIV prevention. We determined the baseline prevalence of low bone mineral density (BMD) and the effect of TDF on
BMD in men who have sex with men (MSM) in a PrEP trial in San Francisco.
Methods/Findings: We evaluated 1) the prevalence of low BMD using Dual Energy X-ray Absorptiometry (DEXA) in a
baseline cohort of 210 HIV-uninfected MSM who screened for a randomized clinical trial of daily TDF vs. placebo, and 2) the
effects of TDF on BMD in a longitudinal cohort of 184 enrolled men. Half began study drug after a 9-month delay to
evaluate changes in risk behavior associated with pill-use. At baseline, 20 participants (10%) had low BMD (Z score#22.0 at
the L2–L4 spine, total hip, or femoral neck). Low BMD was associated with amphetamine (OR=5.86, 95% CI 1.70–20.20) and
inhalant (OR=4.57, 95% CI 1.32–15.81) use; men taking multivitamins, calcium, or vitamin D were less likely to have low
BMD at baseline (OR=0.26, 95% CI 0.10–0.71). In the longitudinal analysis, there was a 1.1% net decrease in mean BMD in
the TDF vs. the pre-treatment/placebo group at the femoral neck (95% CI 0.4–1.9%), 0.8% net decline at the total hip (95%
CI 0.3–1.3%), and 0.7% at the L2–L4 spine (95% CI 20.1–1.5%). At 24 months, 13% vs. 6% of participants experienced .5%
BMD loss at the femoral neck in the TDF vs. placebo groups (p=0.13).
Conclusions: Ten percent of HIV-negative MSM had low BMD at baseline. TDF use resulted in a small but statistically
significant decline in BMD at the total hip and femoral neck. Larger studies with longer follow-up are needed to determine
the trajectory of BMD changes and any association with clinical fractures.
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Introduction
Low bone mineral density (BMD) is common among HIV-
infected individuals [1,2]. The etiology of low BMD in this
population is likely multi-factorial, including the effects of chronic
HIV infection, antiretroviral therapy, and traditional osteoporosis
risk factors (e.g. hypogonadism, low body weight, smoking, and
alcohol use) which are prevalent in HIV-infected individuals
[3,4,5,6,7]. Few data exist on BMD in HIV-uninfected men who
are at risk for HIV infection. Data on the prevalence and
correlates of low BMD in these groups could identify the extent to
which low BMD exists prior to HIV infection and better elucidate
factors contributing to low BMD in the presence or absence of
HIV infection.
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23688There is great interest in using anti-retroviral medication for
HIV prevention as pre-exposure prophylaxis (PrEP) in HIV-
negative individuals at risk for HIV infection [8,9]. In November
2010, results from the Global iPrEx trial were released, demon-
strating that daily oral emtricitabine/tenofovir (TruvadaH) pro-
vided 44% additional protection from HIV infection in men who
have sex with men (MSM) who were provided a comprehensive
package of prevention services [10]. In January 2011, the Center
for Disease Control and Prevention (CDC) issued interim
guidance to health-care providers who may begin to provide
PrEP to their at-risk MSM patients [11]. While the Fem-PrEP trial
in African women sponsored by Family Health International was
stopped early due to futility [12], the Partners PrEP Study [13]
and CDC TDF2 Botswana trial [14] demonstrated over 60%
efficacy of tenofovir-based PrEP regimens in serodiscordant
couples and heterosexual men and women respectively. All
current PrEP trials are testing oral tenofovir disoproxil fumarate
(TDF) alone or in combination with emtricitabine (FTC). While
selected for its favorable safety profile [15,16], long half-life [17],
and penetration into the genital compartment [18,19], TDF use
decreased BMD in HIV-infected patients in randomized clinical
trials [16,20,21]. Cases of fractures and/or osteomalacia during
TDF therapy have been reported [22,23,24,25]. Proposed poten-
tial mechanisms include proximal renal tubular toxicity leading to
hypophosphatemia [2] or reduction in osteoblast gene expression
and function [26]. Evaluating effects of TDF on bone density in
studies of HIV-positive individuals is confounded by the effects of
HIV and other antiretrovirals used in treatment regimens that are
also associated with decreases in BMD [16,21]. Therefore, the
evaluation of BMD in the context of PrEP trials in HIV-uninfected
populations provides a unique opportunity to more directly
evaluate TDF effects on bone. This is particularly important in
the context of TDF use for prevention, where the acceptable
risk:benefit ratio may need to be substantially more favorable than
would be considered sufficient for therapeutic use.
The Centers for Disease Control and Prevention (CDC)
sponsored a PrEP trial evaluating the safety of daily oral tenofovir
among 400 HIV-uninfected men who have sex with men in San
Francisco, Atlanta and Boston [27]. To address these important
questions of skeletal health in HIV-negative men at risk for HIV
infection, a DEXA substudy was conducted at the San Francisco
site. In this paper, we characterize the prevalence of baseline low
bone BMD among HIV-uninfected MSM eligible for enrollment
in this study and determine the effects of TDF on bone density
among men followed longitudinally.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Participants
Between February 2005 and July 2007, 200 participants
enrolled at the San Francisco Department of Public Health site
of the US CDC PrEP study, a phase 2 randomized, double-blind,
placebo-controlled extended safety trial of TDF among MSM in
the United States (Figure 1). Main inclusion criteria included being
male at birth; 18–60 years of age; HIV-1 negative; reporting anal
sex with a man in the past 12 months; adequate renal, hepatic, and
hematologic function; hepatitis B surface antigen negative; normal
urine dipstick or urinalysis; and serum phosphorus, potassium,
sodium, and calcium within normal limits. Participants with a
history of chronic renal disease; known metabolic bone disease; or
current use of nephrotoxic medications or HIV antiretrovirals
were excluded.
Participants were randomized to one of 4 treatment arms: 1)
daily TDF 300 mg beginning at enrollment; 2) daily placebo
beginning at enrollment; 3) daily TDF beginning 9 months after
enrollment; 4) daily placebo beginning 9 months after enrollment
(Figure 2). This immediate vs. deferred treatment design was
intended to permit examination of the effects of pill-taking on risk
behavior. The study statistician developed the allocation scheme
using a permuted blocks randomization scheme in blocks of 8 (2
assignments in each of the 4 arms). Study bottles were filled with
TDF or placebo by Gilead Sciences using these codes. Only the
study statistician and designated individual at Gilead Sciences had
access to treatment assignment codes during the study.
Participants underwent quarterly visits for 2 years, which
included assessment of adverse events, rapid HIV testing, labor-
atory testing for safety monitoring, and a semi-structured question-
naire on sexual and drug use behavior. In the initial version of the
protocol, dual-energy X-ray absorptiometry (DEXA) was per-
formed at enrollment, 12 months, and 24 months in the immediate
arm to evaluate BMD changes over time. After detection of a
number of individuals with low BMD at baseline, a protocol
amendment was approved within 9 months of study initiation to
conduct baseline DEXA measurements in all eligible individuals
during screening, and to exclude individuals with a Z score,22.5
at the lumbar spine (L2–L4), total hip, or femoral neck and
individuals currently receiving treatment for secondary causes of
low BMD. DEXA evaluation was not performed in participants
found to be ineligible prior to DEXA procedures during the
screening process. DEXA scanning was also added for delayed
arm participants at 9 and 24 months of follow-up. Study drug was
discontinued in participants with a .5% drop from baseline and
among HIV seroconverters at the time of first positive rapid HIV
test.
Two analytic cohorts are presented in this paper. First, for the
analysis of prevalence and correlates of low BMD at baseline, we
have included 210 men who had an initial DEXA scan (including
14 men who had a DEXA scan performed during screening but
did not enroll in the study). Second, for the longitudinal analysis of
TDF effect on BMD, we included 184 men who completed a
baseline and at least one DEXA scan during study follow-up.
All participants provided written informed consent prior to
study participation. This study was approved by the Institutional
Review Boards of the University of California, San Francisco and
the CDC.
Bone mineral density assessment
DEXA scanning of the whole-body, hip, and spine was
performed at baseline, 9 months (delayed arm) or 12 months
(immediate arm), and 24 months, using a GE Lunar Prodigy
densitometer with software version 6.70. The reference population
used in the Lunar software are healthy, ambulatory subjects from
the general population who had no chronic diseases affecting bone
and were not taking medications that affected bone [28]. The
database was drawn from studies performed at university medical
centers and clinics in the United States, England and Northern
Europe. T-scores are based on the reference population ages 20–
40; Z-scores were further matched for age, weight, and racial/
ethnic group. In accordance with the International Society for
Clinical Densitometry 2007 Position Statement on BMD reporting
in men younger than age 50 [29], a Z score of #22.0 at either the
total hip, femoral neck, or lumbar spine (L2–L4) was considered
below the expected range for age.
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PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e23688Figure 1. Study design and participant disposition. The baseline only cohort shown in red shading includes 26 men who had only 1 DEXA
scan performed, either during screening or after enrollment. The longitudinal cohort shown in green shading includes 184 men who had a baseline
and at least 1 additional scan during study follow-up. Of the 210 participants who had a baseline DEXA scan, 178 had this scan performed during
screening, and 32 shortly after enrollment (prior to the protocol amendment moving DEXA scans to screening). {Delayed arm participants who
enrolled prior to protocol amendment had baseline DEXA performed at 9 months prior to starting study drug. DEXA, dual energy X-ray
absorptiometry; TDF, tenofovir disoproxil fumarate.
doi:10.1371/journal.pone.0023688.g001
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Sociodemographic characteristics were collected via interview-
er-administered questionnaire at screening. At baseline and
quarterly follow-up visits, adverse events (including clinical
fractures) and concomitant medications were recorded via clinical
interview, and alcohol and drug use were assessed by Audio
Computer-Assisted Self Interview (ACASI). Alcohol use was
categorized as none, light (1–2 drinks/occasion on no more than
1–2 days/week, or 3–4 drinks/occasion, no more than once a
month), moderate (1–2 drinks/occasion on a daily basis or 3–4
drinks/occasion at least 2–3 times/month), or heavy (5–6 drinks/
occasion on a daily basis or 6 or more drinks on any one occasion)
(adapted from Woody et al [30]). Smoking and exercise patterns
and dietary intake of calcium and Vitamin D (Block Calcium/
Vitamin D screener [31]) were collected via a one-time
interviewer-administered questionnaire conducted during or after
study participation. Baseline body weight was calculated using
whole-body DEXA data as the sum of total lean, fat, and bone
mineral content weights. Laboratory testing, including rapid HIV
testing, serum creatinine, phosphorus, and alkaline phosphatase,
was performed at each quarterly visit. Creatinine clearance was
calculated using the Cockroft-Gault formula [32]. Evaluation of
secondary causes was conducted in men with low BMD at
screening or during follow-up and those with .5% decrease from
baseline at L2–L4 or total hip, including testing for thyroid
stimulating hormone, 25-hydroxy vitamin D level, testosterone
level, spot urine calcium/creatinine ratio, and serum parathyroid
level for participants over age 40.
Statistical analysis
Mean Z-scores of the lumbar spine (L2–L4), total hip, and
femoral neck were calculated, and prevalence of low BMD was
determined with exact 95% binomial confidence intervals (CIs).
The observed number of low BMD cases was compared using a 2-
sided exact binomial test to the number that would have been
expected based on reference population data (approximately 2.3%
would have Z scores below 2 standard deviations of the mean,
assuming Z-scores are normally distributed with mean 0 and
standard deviation 1 [33]). The association of sociodemographic
variables and risk factors for low bone mass with baseline BMD
was examined using univariate logistic regression analysis. Mean
percent change in BMD over time was plotted for each anatomic
region by treatment arm, and the proportion of men losing .3%
and .5% BMD from baseline at 24 months at each site was
determined in a pre-specified analysis. These cut-points were
chosen because a 3% loss represents more than expected BMD
loss in a population of healthy men in which BMD should be
stable [34], and a 5% loss corresponds with the approximate BMD
loss seen in post-menopausal women over a 2-year period [35].
Linear mixed models with random intercepts were used to assess
effects of TDF on percent change in BMD from baseline to 12 and
24 months among immediate arm participants, and from 9 to 24
months among delayed arm participants. Comparison between
treatment arms was by intent-to-treat analysis. Preliminary
analyses examining potential interactions between treatment
assignment (TDF/placebo) and study month, as well as between
treatment assignment and arm (immediate/delayed), revealed no
interactions. Therefore, immediate and delayed arms were pooled
to increase power. All models adjusted for month of follow-up scan
(9, 12, or 24) and arm (immediate or delayed). HIV seroconverters
were removed from the analysis at the time of first detection of
infection. Estimated net treatment differences between the TDF
vs. no treatment (either placebo or off-drug period in 1
st 9 months
of delayed arm) groups with 95% CIs and P values for the
differences were calculated. A sensitivity analysis was performed
censoring participants taken off study drug due to low BMD or
.5% decrease in BMD. We also repeated this analysis adjusting
for baseline BMD level, age, race/ethnicity, BMI, creatinine
clearance, and baseline inhalant (poppers, amyl nitrate, nitrous
oxide, or glue) and methamphetamine use. Accounting for the
number of visits available for the primary analyses and the
observed residual standard deviations and within-subject correla-
tions of the BMD percent loss outcomes, the study had 80% power
to detect between-group differences of 0.7 percentage points in
L2–L4 and femoral neck BMD loss, and 0.4 percentage points in
total hip BMD loss. The linear mixed models were estimated using
the xtmixed command in Stata Version 11.2. P values,0.05 were
considered statistically significant.
Results
Study participants
Overall, 359 men were screened for this study in San Francisco,
of whom 210 underwent baseline DEXA examination (Figure 1).
Of the 200 men who enrolled in the study, 4 did not have any
DEXA scans performed; 184 had at least 1 follow-up scan and
were included in the longitudinal analysis. The baseline analysis
cohort included an additional 26 men who had only one scan
performed, comprised of 12 men who enrolled but terminated
early or declined further DEXA scans and 14 men who screened
but did not enroll. Seven men did not enroll because of low BMD
after this criterion was added to the protocol. Baseline participant
characteristics of the longitudinal analysis cohort (broken out by
TDF vs. placebo) and the additional participants in the baseline-
only cohort are shown in Table 1. In comparing the TDF vs.
placebo groups, median age, race/ethnicity, smoking, alcohol and
recreational drug use, concomitant medication use, dietary
calcium and vitamin D intake, exercise patterns, and baseline
laboratory parameters did not differ significantly between the 2
groups. Mean weight, total fat mass, and body mass index (BMI),
but not fat-free mass, were slightly but significantly higher in the
TDF vs. placebo group.
Prevalence and correlates of low BMD at baseline
Among the 210 men who received an initial DEXA scan, 20
men (9.5%, 95% CI 5.9–14.3%) had at least one Z-score#22.0,
with 17 cases at the L2–L4 spine, 5 at the total hip, and 1 at the
Figure 2. Study design. Participants were randomly assigned to one
of four arms. Participants in the 2 immediate arms (TDF vs. placebo)
initiated study drug at enrollment; those in the 2 delayed arms (TDF vs.
placebo) initiated study drug at the 9 month visit. TDF, tenofovir
disoproxil fumarate.
doi:10.1371/journal.pone.0023688.g002
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Characteristic
Baseline only
(n=26)
{
TDF
(n=94)
{
Placebo
(n=90)
{
2-way
P value*
Age (median, range) 38 (21–59) 40 (19–60) 42 (18–60) 0.91
Race n (%)
White 18 (69) 76 (81) 67 (74)
African-American 1 (4) 5 (5) 4 (4)
Asian/Pacific-Islander 2 (8) 7 (7) 3 (3) 0.10
Latino/Hispanic 2 (8) 5 (5) 9 (10)
Other (multiethnic, Native American, Middle Eastern) 3 (12) 1 (1) 7 (8)
Smoking history n (%)
Nonsmoker 38 (51) 35 (47)
Former smoker n/a 18 (24) 27 (36) 0.23
Current smoker (at enrollment) 19 (25) 13 (17)
Alcohol use in past 3 months{
No use 2 (17) 15 (16) 13 (14)
Light use 5 (42) 37 (39) 37 (41) 0.94
Moderate use 4 (33) 38 (40) 35 (39)
Heavy use 1 (8) 4 (4) 5 (6)
Medication use (% reporting use during study) Multivitamin,
calcium or Vitamin D use
Corticosteroid use (oral or topical) 11 (42) 60 (64) 53 (59) 0.55
Anabolic hormone use (testosterone, growth hormone) 2 (8) 16 (17) 14 (16) 0.84
Other muscle building supplements (creatine) 0 (0) 2 (2) 2 (2) 1.00
Antidepressants 1 (4) 6 (6) 4 (4) 0.75
1 (4) 20 (21) 15 (17) 0.46
Recreational drug use (last 3 mo)¥
Inhalants (poppers, amyl nitrate, nitrous oxide, glue) 4 (33) 26 (28) 34 (38) 0.16
Crack/powder cocaine 2 (17) 12 (13) 11 (12) 1.00
Amphetamines 2 (17) 11 (12) 12 (13) 0.83
Sedatives 0 (0) 10 (11) 14 (16) 0.38
Ecstacy 0 (0) 7 (8) 12 (13) 0.23
Ketamine 0 (0) 1 (1) 2 (2) 0.61
GHB 0 (0) 1 (1) 5 (6) 0.11
Any recreational drug use 4 (33) 41 (44) 47 (52) 0.30
Dietary intake (mean)
Daily total calcium intake (mg) 725 771 0.43
Daily supplemental calcium intake (mg) n/a 131 169 0.49
Daily total Vitamin D intake (ug/d) 288 314 0.57
Daily supplemental vitamin D intake (ug/d) 180 196 0.81
Family history of osteoporosis n/a 11 (14) 6 (8) 0.41
Exercise/Dieting (%)
Any exercise 64 (84) 62 (83) 0.83
Weight bearing exercise n/a 64 (85) 62 (83) 0.86
Non-weight bearing exercise 26 (34) 27 (36) 0.87
Dieting in the past 6 mo 20 (27) 19 (25) 1.00
Body composition, mean
DEXA weight (kg) 81.9 85.8 81.5 0.05
BMI (kg/m2) 25.9 27.0 25.8 0.05
Total lean mass (kg) 56.4 59.5 59.3 0.85
Total fat mass (kg) 23 23.1 19.0 0.01
Laboratory parameters (mean)
Bone Mineral Density in a Tenofovir PrEP Trial
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23688femoral neck. Prevalence of low BMD by this measure was
significantly higher than expected (20 vs. 4.8 cases; p,0.001)
under the standard normal assumption. Three individuals had low
BMD at 2 anatomic sites, 2 at the total hip and femoral neck, and
1 at the total spine and femoral neck. In univariate analysis
(table 2), men who used amphetamines (OR=5.9, p,0.01) or
inhalants (OR=4.6, p=0.02) were significantly more likely to
have low BMD at baseline. Men who reported supplemental
calcium/vitamin D use (59%) were less likely to have low BMD
(OR=0.26, p=0.009). Because there were only 12 low BMD
cases among the 196 men with complete baseline covariate data,
multivariable analysis of low BMD was not performed.
Tenofovir Effect on BMD
At 2 of 3 anatomic locations, TDF exposure resulted in a
statistically significant decrease in BMD relative to baseline when
compared to the pre-treatment/placebo group. In the intent-to-
treat analysis, there was a 1.1% mean net decrease in BMD in the
TDF vs. pre-treatment/placebo group at the femoral neck (95%
CI 0.4–1.9%, p=0.004) and an 0.8% net decline at the total hip
(95% CI 0.3–1.3%, p=0.003); at the L2–L4 spine, there was non-
significant evidence for an adverse effect (0.7% decline, 95% CI
20.1–1.5%, p=0.11). After censoring follow-up for individuals
taken off study drug due to a .5% drop in BMD or low BMD on
a follow-up scan, the net loss was 1.2% (p=0.002), 0.8%
(p=0.003), and 0.9% (p=0.039) for the femoral neck, total hip,
and L2–L4 spine respectively. Results were similar after adjust-
ment for baseline BMD, BMI, creatinine clearance, race, age, and
baseline inhalant and amphetamine use.
Trajectories of BMD change over time by anatomic site are
shown in Figure 3. Declines in BMD in the TDF group were most
prominent in the first 12 months of treatment in the immediate
arm, with similar decreases seen in the delayed arm upon initiation
of TDF during the 9 to 24 month period. Initial BMD declines
associated with TDF exposure were most apparent at the femoral
neck. Trajectory plots for placebo recipients or TDF delayed-arm
participants off study drug during the first 9 month period showed
stable or increasing BMD at the total hip and L2–L4 spine and
milder (,1%) declines at the femoral neck. In an exploratory
analysis evaluating a time by treatment interaction, TDF effects on
BMD did not differ at 24 vs. 12 months in the immediate arm.
Estimates of the incremental percent bone loss at 24 vs. 12 months
were +0.37% (95% CI 20.8–1.5, p=0.53) at the femoral neck,
20.12% (95% CI 20.9–0.6, p=0.75) at the total hip, and +0.2%
(95% CI 21.0–1.4, p=0.73) at the L2–L4 spine.
Percent BMD change from baseline in the TDF vs. placebo
groups is shown in Figure 4. A greater proportion of participants
experienced .3% BMD loss at 24 months at the total hip and
femoral neck in the TDF vs. placebo groups. Specifically, 36% vs.
20% lost more than 3% BMD at the femoral neck (p=0.02), 14%
vs. 3% at the total hip (p=0.02), and 17% vs. 15% at the L2–L4
spine (p=0.69). Furthermore, 13% vs. 6% participants experi-
enced .5% loss of BMD at the femoral neck in the TDF vs.
placebo groups, a difference that was not statistically significant
(p=0.13).
Evaluation of secondary causes of low BMD
Secondary evaluation of low BMD was performed in 16/20
participants with low BMD at baseline and revealed Vitamin D
deficiency in 2 men (25-OH vitamin D level: ,4 ng/ml and
11 ng/ml) and hypogonadism (total testosterone=194 ng/ml) in
one individual. Testing was also performed in all 11 cases of .5%
loss in BMD from baseline at the total spine or hip and revealed
hypogonadism (total testosterone=230 ng/ml) in one individual.
Fracture incidence
Among the 184 men enrolled in the longitudinal cohort, there
were 10 participants noted to have fractures: 6 participants in the
TDF group and 4 participants in the placebo group (p=0.75). The
6 participants in the TDF group had a total of 8 fractures; the 4
participants in the placebo group had 4 fractures. All fractures
were trauma-related and assessed by the investigators to be
unrelated to study drug. None of these individuals had a total
spine, total hip, or femoral neck BMD Z score#22.0 at any time
point.
Discussion
In this study, we found a significant proportion (10%) of healthy
HIV-negative MSM at risk for HIV infection had low BMD at
Characteristic
Baseline only
(n=26)
{
TDF
(n=94)
{
Placebo
(n=90)
{
2-way
P value*
Creatinine (mg/dL) 0.95 0.97 0.97 0.66
Creatinine clearance (mL/min) 123 126 120 0.09
Calcium (mg/dL) 9.5 9.6 9.7 0.69
Phosphorus (mg/dL) 3.6 3.5 3.5 0.94
Serum alkaline phosphatase (g/dL) 75 70 73 0.57
Mean BMD at baseline (g/cm
2)
L2–L4 spine 1.12 1.25 1.24 0.86
Total hip 0.99 1.09 1.07 0.48
Femoral neck 0.98 1.06 1.04 0.52
{Baseline only=participants with only 1 DEXA performed; includes 14 screen failures.
{TDF/placebo=participants randomized to TDF or placebo who had at least 1 follow-up DEXA and were included in the longitudinal cohort.
*P value compares TDF vs. placebo arms of longitudinal cohort.
¥For baseline only group, alcohol and recreational drug use data available for 12/26 participants who enrolled in the study.
DEXA, dual energy X-ray absorptiometry; TDF, tenofovir disoproxil fumarate; BMD, bone mineral density.
doi:10.1371/journal.pone.0023688.t001
Table 1. Cont.
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criteria have shown a higher than expected prevalence of low
BMD among HIV-infected MSM, including men with primary
HIV infection [36], little data exist on bone mass in healthy MSM
without HIV infection. Our findings suggest that some degree of
the low BMD observed in HIV-infected men may pre-date HIV
infection. We used ISCD classification criteria for BMD reporting
in men younger than age 50. These guidelines stipulate that
T-scores should not be used and a Z-score of #2.0 is defined as
‘‘below the expected range for age’’ [29]; it is emphasized that in
men in this age group, osteoporosis cannot be diagnosed on the
basis of BMD alone. While the BMD reference ranges for men
used in this study may not fully represent the current population
studied, men with a Z-score#22.0 fall within the lowest 2.5
percentile of BMD compared with the reference population and
are typically evaluated for secondary causes of low BMD if their
Table 2. Selected Parameters Associated with Low Bone Mineral Density (Z score#22.0).
Characteristic Univariate OR 95% CI P
Age (yrs) 0.98 0.94–1.03 0.46
Race
White (ref)
African-American 1.17 0.14–9.89 0.89
Asian/Pacific-Islander n/a
{ n/a n/a
Latino/Hispanic 1.50 0.31–7.28 0.62
Other 3.94 0.94–16.5 0.06
Tobacco use*
Never (ref)
Former 1.69 0.40–7.12 0.47
Current 1.11 0.19–6.37 0.91
Alcohol use (past 3 mo)
{
None (ref)
Light 1.55 0.17–14.4 0.70
Moderate 2.90 0.34–24.6 0.33
Heavy n/a
{ n/a n/a
Medication use
Multivitamin, calcium or Vitamin D use 0.26 0.10–0.71 ,0.01
Corticosteroid use n/a
{ n/a n/a
Anabolic hormone use (testosterone) n/a
{ n/a n/a
Other muscle building supplements/compounds n/a
{ n/a n/a
Antidepressants 0.83 0.23–3.03 0.79
Recreational drug use (past 3 mo)
{
Amphetamine 5.86 1.70–20.20 ,0.01
Inhalants 4.57 1.32–15.81 0.02
Cocaine 2.45 0.62–9.76 0.20
Sedatives 0.64 0.08–5.16 0.67
Ecstasy 3.48 0.85–14.16 0.08
GHB 3.24 0.35–30.15 0.30
Daily total calcium intake (per 100 mg increase) 0.97 0.83–1.13 0.69
Daily total vitamin D intake (per 100 IU increase) 0.84 0.62–1.13 0.25
Family history of osteoporosis* 1.02 0.12–8.66 0.99
Any exercise* 0.75 0.15–3.75 0.72
,1 hour/day 1.02 0.12–8.66 0.99
1–2 hours/day 0.53 0.07–4.05 0.55
2–3 hours/day 2.13 0.38–12.03 0.39
.3 hours/day 0.64 0.05–7.62 0.72
Body mass index
{ 1.11 0.95–1.29 0.17
{BMI, alcohol, and recreational drug use data were available in 196 subjects who enrolled.
{There were no cases of low BMD among Asian/Pacific Islander men, heavy alcohol users, and those who reported use of corticosteroids, anabolic hormones, or muscle
building supplements.
*Tobacco use and exercise/family history data available in 155 participants who enrolled.
doi:10.1371/journal.pone.0023688.t002
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PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e23688bone density comes to medical attention. In testing 16 such
individuals, we uncovered 2 cases of low vitamin D and one case of
hypogonadism, suggesting the importance of pursuing a work-up
for reversible causes in this population. However, the implications
of low BMD for fracture risk in this cohort, particularly among
younger men, are currently unknown.
Low BMD was associated with amphetamine and inhalant use
in our study, while men reporting use of multivitamins and
supplements containing calcium or vitamin D were less likely to
have low BMD. A review of the literature shows two reports of a
potential association between methamphetamine use and low
BMD/altered bone metabolism [37,38]. The association of
methamphetamine and inhalant use with low BMD could be
due to a direct toxic effect of these substances on bone metabolism
[39], or may be confounded by another lifestyle factor that is
associated with both drug use and low BMD. Experimental studies
examining potential biological mechanisms for methamphetamine
and inhalant-induced bone loss should be conducted, along with
larger cross-sectional and cohort studies of drug-using populations
to confirm and further investigate these associations. Several
studies have found an independent association of amphetamine
and/or inhalant use with HIV acquisition among MSM in the
United States [40,41,42]; this substance-using population may be
more likely to benefit from PrEP if effective, but also to
demonstrate low BMD at baseline.
Among men who enrolled in this PrEP trial and were included
in the longitudinal analysis, TDF use resulted in a small (0.8–1.1%)
but statistically significant net decrease in BMD from baseline at
two anatomic sites, with the greatest loss at the femoral neck.
These changes occurred within the first 12 months of tenofovir
use, with no evidence of further declines in BMD at 24 months in
the immediate arm, although our sample size limited power to
examine differences in the treatment effect across the two time
points. We also observed a higher proportion of men experiencing
a .5% drop in BMD from baseline in the TDF group relative to
placebo, particularly evident at the femoral neck, but this
difference was not statistically significant.
Prior studies have demonstrated BMD loss with initiation of
ART, regardless of regimen, with somewhat greater decreases
observed with tenofovir-containing regimens [6,16,21,43,44]. Our
results are consistent with findings of decreased BMD associated
with TDF seen in earlier randomized trials of antiretroviral-naive
HIV-infected individuals. The difference in BMD decline
associated with TDF compared with placebo in this study is
similar in magnitude to the net BMD decline associated with
TDF-containing regimens versus alternative regimens in treatment
studies. In the Gilead 903 study, Gallant et al. demonstrated a net
decrease in BMD of 1.2% at the lumbar spine in the TDF vs. d4T
arms; bone loss in the TDF group occurred through weeks 24 and
48 in this cohort and stabilized through week 144 [16]. No
additional bone loss was seen in a subgroup of Gilead 903
participants followed through 288 weeks [45]; participants in this
open-label extension received supplemental calcium and vitamin
D. In the more recent ASSERT trial, Stellbrink et al. reported a
net 0.8% and 1.7% decrease in BMD at the lumbar spine and total
hip respectively, when comparing the tenofovir-emtricitabine vs.
the abacavir-lamivudine group [21]. In this European cohort,
bone loss in the TDF group stabilized at week 24 at the lumbar
spine but ongoing loss occurred through week 48 at the total hip.
Given the relatively short duration of follow-up in most these
studies, longer term BMD data are required to better characterize
the long-term effects of TDF on BMD. Current PrEP trials are
testing tenofovir-based regimens in over 20,000 HIV-uninfected
individuals at risk for HIV infection. Several of these trials are
measuring BMD in a subset of study participants, including the
iPrEx trial, a phase 3 efficacy trial of emtricitabine-tenofovir in
MSM globally. Given our findings, we encourage other PrEP trials
to include DEXA monitoring when logistically possible to better
characterize the baseline prevalence of low BMD in different
target populations for PrEP and the prevalence of risk factors for
low BMD, and determine the magnitude and trajectory of BMD
loss associated with ARV use for prevention. These data may help
identify individuals who are at risk for low BMD or bone loss with
PrEP use and guide clinical decision making on whether screening
for low BMD may be warranted prior to initiation of PrEP.
The clinical significance of TDF-associated BMD loss, including
whether fracture risk is increased, is currently unknown [46]. In
this study, we observed 6 fractures in the TDF group vs. 4 in the
placebo group, although this study was not designed or powered to
detect differences in fracture rates between arms. All fractures
were trauma-related and assessed as unrelated to study drug. In
the Gilead 903 study, 16 patients (11 in the stavudine group vs. 5
in the tenofovir group) developed fractures through 144 weeks,
and almost all were related to trauma [16]. However, there have
been case reports of fractures during TDF therapy, in the setting of
proximal renal tubule dysfunction. Additional follow-up in larger
cohorts is needed to determine whether extended use of TDF
increases fracture risk.
Our study is subject to some limitations. First, this study was
conducted in only 1 site (San Francisco) in HIV-uninfected men,
the majority of whom were white. Additional studies are being
conducted in different settings and in other populations, including
HIV-uninfected women, and will determine whether our findings
can be generalized. Second, we had a relatively small sample size,
precluding multivariable analysis of factors associated with low
BMD at baseline, as well as analyses to identify any subgroups at
higher risk for BMD loss during TDF PrEP use. Also, our pre-
valence estimate for baseline low BMD was based on a con-
venience sample of men screening for an HIV prevention study.
Therefore, these results may not reflect the prevalence of low
BMD in the larger population of MSM. Our study employed
relatively short follow-up (maximum 24 months for immediate
arm participants). Additional studies are needed to determine
whether BMD effects of TDF are sustained or progress during
longer term use, and whether these effects reverse after TDF
discontinuation. Also, we did not have the opportunity to do more
extensive testing for secondary causes of low BMD or to evaluate
markers of bone mineral turnover to help elucidate mechanisms
for TDF-associated bone loss. In the ASSERT study, increases in
bone turnover markers (including osteocalcin, procollagen 1 N-
terminal propeptide, bone specific alkaline phosphatase, and type
1 collagen cross-linked C telopeptide) were significantly greater in
the TDF vs. comparator group [21]. Future studies should
incorporate testing of markers of bone resorption and formation to
evaluate potential mechanisms for BMD loss associated with TDF.
Figure 3. Mean percent change in BMD from baseline at the total spine, total hip, and femoral neck. Trajectory of mean percent change
in BMD at the femoral neck (a), total hip (b), and L2–L4 spine (c), by treatment arm. Solid lines represent the immediate arm, and dashed lines
represent the delayed arm. Participants who discontinued study drug due to .5% BMD loss from baseline are included. BMD, bone mineral density.
doi:10.1371/journal.pone.0023688.g003
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drug. Lesser drug exposure due to suboptimal pill-use may have
attenuated the magnitude of effects of TDF on BMD we detected
in this study. Optimally, such analyses would be adjusted using a
biologic marker of long-term drug exposure. Such measures,
including tenofovir concentrations in peripheral blood mononu-
clear cells and hair [47], are currently being explored and should
be correlated with bone turnover markers and BMD outcomes in
future TDF-based PrEP studies.
Our study also has several strengths. We present novel data
looking at prevalence of low BMD in HIV-uninfected men at risk
for HIV infection and the effects of TDF on BMD in this
seronegative population. These data provide important informa-
tion on skeletal health in men in the absence of HIV infection and
other antiretroviral use. For the longitudinal analysis, this study
utilized an intent-to-treat analysis of this randomized, placebo-
controlled cohort, thus avoiding confounding by indicator in our
assessments. We also achieved high levels of follow-up during the
trial.
In summary, we found a significant proportion of HIV-
uninfected men had low BMD at baseline. Low BMD was
associated with methamphetamine and inhalant use. Similar
adverse effects of TDF on BMD were seen in this cohort of HIV-
uninfected MSM as seen in antiretroviral treatment studies of
TDF-based regimens in HIV-infected individuals. These data
suggest that low BMD may pre-date HIV infection among men at
risk for acquisition of HIV, and use of tenofovir in these
individuals leads to a small but statistically significant decline in
BMD. The decline was not associated with an elevated fracture
risk during the study.
The finding that oral FTC/TDF PrEP reduces HIV acquisition
among MSM [10] and the issuance of interim guidance on
prescribing PrEP from the CDC to health-care providers [11] will
likely lead to increased PrEP use in different MSM communities.
Larger controlled studies with longer follow-up are needed to
assess the course of BMD loss associated with tenofovir-based
PrEP regimens over the longer term, as well as the clinical
significance of these findings in HIV-uninfected populations.
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